

Our Ref: DC/NB

8th September 2020

Website: www.barnsleyccg.nhs.uk
<http://twitter.com/nhsbarnsley>
www.facebook.com/nhsbarnsley

To: Prescribing Clinicians and Pharmacists within the Barnsley locality

Dear Colleague

Re: Summary of Key Points from the Area Prescribing Committee Meeting on 12th August 2020

The main outcomes of the meeting were: -

Prescribing Guidelines

The following prescribing guidelines were approved by the Committee:

Anticoagulation for Stroke Prevention in Non-Valvular Atrial Fibrillation: Joint primary and secondary care guidance [UPDATED]

This document provides guidance to primary and secondary care prescribers in selecting the most suitable anticoagulant for each patient and conducting appropriate baseline and ongoing monitoring. It replaces the previous guideline 'Considerations for Anticoagulation in NVAf for Primary Care'.

Patients at extremes of body weight

The guidance notes that there is limited data available on the use of DOACs in patients weighing less than 50kg or more than 120kg and that there may be a risk of over or under anticoagulation respectively. Warfarin treatment may be preferable to DOACs in such patients since anticoagulation can be monitored using INR. Use of DOACs in these patient groups should be based on discussion with the patient taking into account individual bleeding risk and other patient specific factors. Where uncertainty remains, individual patients may be discussed with the relevant specialists.

The updated guideline will be uploaded to the BEST website in due course. The previous NOAC prescriber decision support and NOAC SYB policy have been superseded by this guidance and will be removed from the BEST website.

Drugs prolonging the QTc interval and palliative care [UPDATED]

This guideline has received minor amendments and is available on the BEST website at the following link:

https://best.barnsleyccg.nhs.uk/clinical-support/medicines/prescribing-guidelines/Drugs_prolonging_the_QTc_interval_and_palliative_care.pdf

Use of Calcium and Vitamin D post Fragility Fracture [NEW]

This guideline summarises the use of calcium and vitamin D post fragility fracture and is available on the BEST website at the following link:

<https://best.barnsleyccg.nhs.uk/clinical-support/medicines/prescribing-guidelines/Use%20of%20Calcium%20and%20Vitamin%20D%20post%20Fragility%20Fracture.pdf>

If vitamin D alone is prescribed post fragility fracture (instead of calcium and vitamin D), for example where calcium intake is relatively high, or hypercalcaemia is present, the discharge letter should be annotated with the reason why additional calcium supplementation is not recommended.

Prescribing guidelines are available on the BEST website:

<http://best.barnsleyccg.nhs.uk/clinical-support/medicines/prescribing-guidelines/>

The Barnsley Joint Formulary can be accessed at the link below:

<http://www.barnsleyformulary.nhs.uk/>

Shared Care / Amber-G Guidelines

The following shared care guidelines were approved by the Committee:

Colesevelam Amber-G Guideline [NEW]

Colesevelam can be used for the treatment of bile acid malabsorption (unlicensed indication), second line, when patients cannot tolerate colestyramine.

The amber-G guideline is available on the BEST website at the following link:

<https://best.barnsleyccg.nhs.uk/clinical-support/medicines/shared-care-guidelines/Colesevelam%20Amber%20G.pdf>

Dalteparin Shared Care Guideline for use in the Treatment and Prophylaxis of Venous Thromboembolism (NON PREGNANT patients) [UPDATED]

The shared care guidance has been updated.

Dalteparin Amber-G Guideline for use in the Treatment and Prophylaxis of Venous Thromboembolism IN PREGNANCY [UPDATED]

The classification of dalteparin in **pregnancy** has been changed from amber to **amber-G** and a separate amber-G guideline has been developed.

The guidelines will be uploaded to the BEST website in due course.

Shared Care and Amber-G guidelines are available on the BEST website:

<http://best.barnsleyccg.nhs.uk/clinical-support/medicines/shared-care-guidelines/>

Prescribers (including secondary care clinicians) are encouraged to report any problems they experience with shared care or other medicines related issues, particularly where guidelines are not being complied with, to the following email address: BarnsleyAPCReport@nhs.net.

The Barnsley Interface Issues Form should be used to report such problems:

<http://www.barnsleyccg.nhs.uk/members-professionals/area-prescribing-committee.htm>

Traffic Light Classifications

The Committee assigned the following classifications to the products included in the table below:

Drug	Formulary Indication	Traffic light status (Drugs with a provisional classification are not currently included on the Barnsley formulary)
Horizon Scanning Document – July 2020		
Insulin lispro 100 units/mL solution for injection in vial, cartridge, pre-filled pen, & junior pre-filled pen. 200 units/mL pre-filled pen (Lyumjev[®]▼ , Eli Lilly and Company Limited)	Diabetes mellitus in adults.	Non-formulary provisional grey Insulin Lispro (Humalog[®]) is formulary green
Infections Formulary Review Primary Care antimicrobial guidelines available at: https://best.barnsleyccq.nhs.uk/clinical-support/medicines/prescribing-guidelines/Barnsley%20Primary%20Care%20Antimicrobial%20Guideline.pdf?UNLID=4771762352020818135133 BHNFT Antimicrobial Policy for Adults available at: http://barnsleybest.nhs.sitekit.net/clinical-support/medicines/prescribing-guidelines/BHNFT%20Antimicrobial%20Policy%20-%20Secondary%20Care.pdf?UID=477176396202081814935		
Sodium Fusidate (250mg tablets, 500mg infusion)	Antibacterial	Formulary red (previously formulary green)
Fosfomycin	Antibacterial	Formulary red (previously formulary amber-G)
Streptomycin	Antibacterial	Formulary red
Moxifloxacin	Antibacterial	Formulary grey
Cefixime	Antibacterial	Formulary grey
Levofloxacin	Antibacterial	Formulary grey (previously formulary green)
CNS Formulary Review (04.01 – 04.04)		
Benperidol	Control of deviant antisocial sexual behaviour	Formulary grey (previously formulary amber-G)
Lithium Carbonate (Camcolit MR)	Treatment and prophylaxis of mania/bipolar disorder/recurrent depression/aggressive or self-harming behaviour	Formulary amber
Doxepin	Depressive illness (particularly where sedation is required)	Formulary grey restricted (previously formulary green restricted)
New Product Application		
Actikerall[®] Cutaneous Solution (fluorouracil/ salicylic acid)	Topical treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (grade I/II) in immunocompetent adult patients.	Formulary amber-G Amber-G guidance currently in development.

MHRA Drug Safety Update

The July 2020 MHRA Drug Safety Update can be accessed at the following link:

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/905690/July-2020-DSU-PDF.pdf

There were no issues relating to primary care this month.

Regards



Deborah Cooke
Lead Pharmacist

cc: Medicines Management Team
Rebecca Hoskins, BHNFT
Sarah Petty, BHNFT
Mike Smith, BHNFT
Sarah Hudson, SWYPFT
Area Prescribing Committee Members (Secretary to the APC to circulate)
Local Medical Committee (Secretary to the LMC to circulate)
Gary Barnfield, NHS Sheffield CCG
Alex Molyneux, NHS Doncaster CCG
Stuart Lakin, NHS Rotherham CCG